By Andrew Ciupek,  PhD, Senior Manager, Clinical Research, GO2 for Lung Cancer and Daniel A. Saez, MSc, Navigator, Treatment & Trials, GO2 for Lung CancerNew Hope for Patients with KRASUntil recently, the KRAS mutation was considered un-targetable in most types [...]